The Pediatric Oncology Branch's

Leukemia, Lymphoma, Transplant and Cell Therapy Team

Our highly trained team is focused on developing and conducting a wide range of clinical trials in a quest to improve outcomes for children, adolescents, and young adults with leukemias and lymphomas.


Although cure rates are excellent for many subtypes of childhood leukemia and lymphoma, new approaches are needed to overcome resistance to standard therapies and to decrease treatment-associated sequelae in survivors of pediatric cancer.

Our goal, as the Leukemia, Lymphoma, Transplant and Cellular Therapy Team of the Hematologic Malignancies Section, is to develop cutting-edge, early-phase clinical trials for patients with high-risk hematologic malignancies, with a specific focus on developing novel therapies which can overcome chemotherapeutic or immunotherapeutic resistance. The trials implemented by our section seek to improve upon existing strategies, or address unmet needs, and incorporate the study of leukemia biology to optimize outcomes.

Our group is specifically focused on advancing CAR T-cell therapy for children and young adults with acute leukemias and lymphomas. Our focus is on using CAR T-cells to target new tumor markers in acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) and learn how to best deliver this care safely and effectively.

A picture of the shah research team in the Clinical Center courtyard.
From Left to Right: Sara Silbert, Monica Epstein, Bonnie Yates, Haneen Shalabi, Nirali Shah, Anupam Verma, Elizabeth Holland, and Angela Sarkisian.

Our team is a member of the CARnation Consortium, a group of expert researchers and clinicians treating pediatric hematologic malignancies with immunotherapy. 

Doctor talking to a pediatric patient

Patients & Providers

We conduct collaborative clinical trials that focus on developing targeted agents and applying immunotherapy to treat high risk childhood leukemias and lymphomas that do not respond to chemotherapy. Our patients come to us from all over the world to receive treatment when previous therapies have failed. To learn more about our clinical trials, please contact our team.


Contact Our Team

240-858-3536 (Lauren Little, RN) or 240-383-6185 (Toni Foley, RN)